Semaglutide vs Tirzepatide: The GLP-1 Class Landscape

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetics behind every metabolic decision. Browse all Peptides & GLP-1 education

This is an independent editorial overview. PlexusDx has no commercial relationship with the manufacturers of the products discussed.

Semaglutide and tirzepatide anchor a wider GLP-1 family, and understanding either one is easier once you can see the whole class map. This overview, current as of April 2026, places the leading incretin molecules in context — their receptor design, approval timeline, evidence base, safety, and price band — before turning to the inherited biology common to all of them.

Where each molecule sits in the GLP-1 family

Semaglutide (Novo Nordisk) and tirzepatide (Eli Lilly) are both GLP-1 pathway compounds, but they are not built alike. Tirzepatide is a GIP/GLP-1 dual agonist; semaglutide, liraglutide, and dulaglutide are GLP-1-selective receptor agonists; and retatrutide is an investigational GLP-1/GIP/glucagon triple agonist that is not FDA-approved as of April 2026. Every one of them engages the GLP-1 receptor and modulates gastric emptying, post-meal glucose, and satiety signaling. Grouping them this way clarifies that the real debate is less semaglutide-versus-tirzepatide and more selective-versus-dual-agonist design within one shared receptor family.

A timeline of approvals across the class

FDA clearance depends on indication: Victoza (liraglutide) for type 2 diabetes in 2010; Trulicity (dulaglutide) for diabetes in 2014; Ozempic (semaglutide) for diabetes in 2017; Rybelsus (oral semaglutide) for diabetes in 2019; Wegovy (semaglutide 2.4 mg) for chronic weight management in 2021; Mounjaro (tirzepatide) for diabetes in 2022; Zepbound (tirzepatide) for weight management in 2023 and for obstructive sleep apnea in 2024. Retatrutide remains investigational. Reading the dates in order also shows how quickly the class expanded from diabetes-only approvals toward dedicated weight-management and sleep-apnea indications.

Trial programs that built the evidence

The published record spans STEP and SUSTAIN and SELECT for semaglutide; SURMOUNT and SURPASS and SURMOUNT-OSA for tirzepatide; LEAD and LEADER for liraglutide; and AWARD for dulaglutide. Two head-to-head reads matter: SUSTAIN 7 compared semaglutide 1 mg with dulaglutide 1.5 mg, and SURPASS-2 compared tirzepatide with semaglutide 1 mg in type 2 diabetes. Different populations and endpoints mean per-trial reading beats sweeping class claims.

Class-wide safety and the boxed warning

Every FDA-approved GLP-1 receptor agonist and GIP/GLP-1 dual agonist carries the class boxed warning for thyroid C-cell tumor risk observed in rodent studies, and all are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Gastrointestinal symptoms dominate the common side effects; rare serious events include pancreatitis, gallbladder disease, and dehydration-related acute kidney injury.

What list prices look like across the category

As of April 2026, list prices for the FDA-approved brands span roughly $815–$1,620 per month at U.S. list price (manufacturer published pricing). What a person actually pays depends on insurance coverage, the indication written on the prescription, manufacturer savings-card eligibility, and whether a compounded alternative is available through a licensed compounding pathway. That band reflects branded list prices, and compounded alternatives dispensed through licensed pathways are priced on a separate basis entirely.

The inherited variables under the whole class

No matter which molecule a clinician selects, the genetic groundwork is shared. Variants in FTO (appetite and adiposity set-point), GLP1R (the receptor every GLP-1 compound targets), MC4R (a melanocortin receptor central to energy balance), and TCF7L2 (glucose homeostasis and GLP-1 secretion) shape the terrain each compound works on. The PlexusDx Precision Peptide Genetic Test maps 14 pathways, 49 peptides, 150+ genetic insights across these pathways — context, not a response prediction.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. It does not sell, prescribe, or recommend dulaglutide, liraglutide, retatrutide, or other GLP-1 compounds beyond semaglutide and tirzepatide. Starting with the biology is the test-before-you-invest approach.

Related reading on PlexusDx: Wegovy Uses, Wegovy Cost, Wegovy for Weight Loss, Wegovy Price.

Frequently Asked Questions

How do the molecules in this class differ?

Receptor engagement separates them: tirzepatide is a dual GIP/GLP-1 agonist, while semaglutide, dulaglutide, and liraglutide are GLP-1-selective. Retatrutide is an investigational triple agonist. Half-life and dosing frequency also vary across these molecules, which shapes how often each is administered and how it is titrated.

Is retatrutide available to buy?

No. Retatrutide is an investigational GLP-1/GIP/glucagon triple agonist and is not FDA-approved as of April 2026. It is not sold by PlexusDx and is not part of any protocol here. Any discussion of it is educational only, without dosing, technique, or sourcing guidance.

Which class member reduces weight most?

Head-to-head weight data is trial-specific and limited. SURPASS-2 showed larger mean weight reduction with tirzepatide than semaglutide 1 mg in type 2 diabetes, though weight-management trials used different endpoints. Individual response varies, so discuss the options with a qualified healthcare provider.

What does the genetic test add across this class?

The Precision Peptide Genetic Test never predicts response to any compound and never reads drug response. It analyzes pathway-level variants in FTO and MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology — upstream context that applies across every molecule in the class.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.